Katia Bassett
Associate Director, Translational Research Geron
Talk Title: Progression-free survival (PFS) in patients with short tumor telomere length: Subgroup analysis from a randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced NSCLC
Talk Time: Stream 1 PM, 19th June Read more...
Bob Beckman
Executive Director, Clinical Research Oncology Daiichi-Sankyo
Talk Title: Best practice in integration of state-of-the-art biomarker strategies
Talk Time: Stream 1 PM, 19th June
Carol Berry Senior Vice President & GM Pharmacogenomics Services Division Asuragen Talk Title: PANEL SESSION: Mass spectrometry technique advancement & what this means for biomarker validation Talk Time: Stream 2 PM, 19th June
Jack Bloom
President Bloom Consulting Services LTD
Talk Title: Workshop B: The Evolving Role of Strategic Partnerships and Collaborations in Biomarker and Companion Diagnostics Development Today
Talk Time: 18th June, 1pm
Mark S. Boguski
Associate Professor, Center for Biomedical Informatics Harvard Medical School
Talk Title: Big Data + analytics = precision diagnoses and better outcomes
Talk Time: Plenary session AM, 19th June
Katherine Bonter
Director of Promotion & Advocacy CEPMED
Talk Title: Current trends and challenges facing innovation and commercialization of personalized medicine
Talk Time: Plenary session AM, 20th June
Jen Bowman
Vice President, Regulatory Affairs & Policy ACLA
Talk Title: Bridging policy & business strategy: Examining health economic impacts of MDx development
Talk Time: Plenary session AM, 20th June
Cynthia Brogdon
Group Director, Oncology Medical Strategy, Global Development Lead, Erbitux Bristol-Myers Squibb
Talk Title: Navigating the commercial landscape of personalized oncology drug development
Talk Time: Plenary session AM,
19th June
David Brooks
Medical Head of Translational Development TESARO
Talk Title: State-of-the-art translational strategies for oncology drug development
Talk Time: Stream 2 PM, 19th June
Richard Buller
Vice President of Translational Oncology Pfizer
Talk Title: Challenges and opportunities for drug development with biomarker negative populations
Talk Time: Stream 1 PM, 19th June
Devon Campbell
Director and Head of Engineering & Systems Novartis
Talk Title: Ensuring product quality standards across FDA/CLIA labs for MDx tests and IVD systems
Talk Time: Plenary session PM, 19th June
Peter Choyke
Senior Investigator National Cancer Institute
Talk Title: Oncologic molecular
imaging: Promises and challenges
Talk Time: Stream 1 PM, 19th June
Chris Coughlin
Director of Clinical Development Morphotek
Talk Title: Tackling the verification and validation bottlenecks: Why are we still facing challenges?
Talk Time: Stream 2 PM, 19th June
David Dworaczyk
Chief Operating Officer Meta Diagnostic
Talk Title: PANEL SESSION: Allaying fears and ending uncertainties regarding reimbursement: What does the industry need in terms of knowledge and support?
Talk Time: Plenary session AM, 20th June
Benjamin Eckert
Director, Global Health Economics & Pricing Novartis
Talk Title: PANEL SESSION: Allaying fears and ending uncertainties regarding reimbursement: What does the industry need in terms of knowledge and support?
Talk Time: Plenary session AM, 20th June
Ron Eisenstein
Partner Nixon Peabody
Talk Title: Workshop C: Understanding the PTO’s Rules Implementing Prometheus With Respect To Medical Diagnostic Claims
Talk Time: 18th June, 4pm
David Fenstermacher
Chair, Department of Biomedical Informatics Moffitt
Talk Title: Updates on novel usage of molecular markers for clinical trial matching
Talk Time: Stream 1 PM, 20th June
Keith Fournier
Director, Global Regulatory Affairs AbbVie
Talk Title: Examining routes and options for regulatory approval success in personalised medicine
Talk Time: Plenary session PM, 19th June
Abdel Halim
Director, Clinical Biomarkers Daiichi-Sankyo
Talk Title: Molecular DX in cancer drug development: why it’s challenging
Talk Time: Stream 1 AM, 19th June
Matt Hawryluk
Director of Business Development Foundation Medicine
Talk Title: Winning the genomic technology arms race: A technical and commercial perspective
Talk Time: Stream 2 PM, 20th June
Joerg Heyer
Director, Cancer Biology AVEO
Talk Title: Harnessing signaling
pathways for biomarker discovery
Talk Time: Stream 1 AM, 19th June
Michael Hodsdon
Associate Professor of Laboratory Medicine & Pharmacology Yale University
Talk Title: PANEL SESSION: Mass spectrometry technique advancement & what this means for biomarker validation
Talk Time: Stream 2 PM, 19th June
Shidong Jia
Scientist Genetech
Talk Title: Phospho flow pharmacodynamic assays for clinical trials
Talk Time: Stream 1 PM, 20th June
Feng Jiang
Associate Professor, Pathology University Of Maryland
Talk Title: Understanding genomic aberrations leading to tumor formation and translating into the clinic
Talk Time: Stream 2 PM, 20th June
Chris Jowett
Companion Diagnostics Global Commercial Head Abbot Molecular
Talk Title: Companion diagnostic success: Biomarker discovery to global commercialization
Talk Time: Plenary session AM, 19th June
Scott Kahn
Chairman, Biomarkers Council. International Cancer Advocacy Network (ICAN)
Talk Title: Examining future reimbursement options for whole genome sequencing
Talk Time: Plenary session AM, 20th June
Mark Kass
Partner Nixon Peabody
Talk Title: Charting the true effects of recent healthcare legislation on personalized medicine
Talk Time: Plenary session PM, 19th June
Areta Kupchyk
Partner Nixon Peabody
Talk Title: Regulatory Pathways for Companion Dx: Engaging FDA, Expediting Review, and Linking Market Exclusivity
Talk Time: 18th June, 4pm
Towia Libermann
Associate Professor of Medicine Beth Israel Deaconess Medical Centre
Talk Title: Bridging genomics and cancer diagnostic development: What gaps still remain?
Talk Time: Stream 2 PM, 20th June
Len Lichtenfeld
Deputy Chief Medical Director American Cancer Society
Talk Title: Adapting patient care to the personalized medicine environment
Talk Time: Plenary session PM, 20th June
Patricia LoRusso
Professor of Medicine, Director of the Phase I Clinical – Pharmacology Team Barbara Ann Karmanos Cancer Institute
Talk Title: Conducting personalized medical trials to improve treatment of patients with BRAF wild-type melanoma
Talk Time: Stream 1 PM, 20th June
Ron Mazumder
Global Head, Research & Product Development Janssen
Talk Title: Realities of integrating genomic advances into companion diagnostic development
Talk Time: Stream 2 AM, 20th June
Ian McCaffery
Oncology Biomarker Development, Companion Diagnostics Genetech
Talk Title: Examining the effects of optimized validation strategies on clinical development study size and timeframes
Talk Time: Stream 1 AM, 19th June
Alexander Miron
Assistant Professor, Cancer Biology Dana-Farber Cancer Institute
Talk Title: Applying novel genomic techniques and methodologies in development of novel diagnostics for breast cancer
Talk Time: Stream 2 PM, 20th June
George Naumov
Senior Research Biologist - Oncology MERCK
Talk Title: Biomarker selection in the development of two novel compound combinations
Talk Time: Stream 2 PM, 19th June
Marina Nikiforova
Associate Professor of Pathology UPMC
Talk Title: Developing multi-gene molecular panels using next generation sequencing platforms
Talk Time: Stream 2 PM, 20th June
Vince O’Neill
Global Head of Personalized Medicine & Companion Diagnostics sanofi aventis
Talk Title: Clinical trial design in the age of Personalized Medicine
Talk Time: Stream 1 AM, 20th June
Jonathan Pan
Director, Oncology Companion Diagnostic & Disease Strategy GSK
Talk Title: The importance of building a technology infrastructure and workflow for the optimization of MDx development
Talk Time: Stream 1 PM, 19th June
Sonia Pearson-White
Director The Biomarkers Consortium
Talk Title: I-SPY-2 & the role of imaging biomarkers in the clinical setting
Talk Time: Stream 1 PM, 20th June
Tharaknath Rao
Group Medical Director Novartis
Talk Title: A roadmap for ensuring the highest standards of performance in MDx clinical trials
Talk Time: Stream 1 PM, 20th June
David Resnick
Partner Nixon Peabody
Talk Title: Workshop C: Understanding the PTO’s Rules Implementing Prometheus With Respect To Medical Diagnostic Claims
Talk Time: 18th June, 4pm
David Shames
Scientist Genetech
Talk Title: Using DNA methylation of specific genes as molecular diagnostics
Talk Time: Stream 2 PM, 20th June
Miro Venturi
Site Head, Oncology Biomarkers Roche
Talk Title: Future applications of CTCs as a biomarker in drug development
Talk Time: Stream 1 PM, 19th June
Thomas Wickham
Vice President, Research & Development Merrimack
Talk Title: Designing and conducting trials using predictive diagnostic PET-imaging agents
Talk Time: Stream 1 PM, 20th June
Brenda Yanak
Director of Clinical Innovation Pfizer
Talk Title: Advancements in biospecimen handling and how this directly underscores diagnostic development
Talk Time: Stream 1 AM, 20th June
Yihong Yao
Director, Head of Pharmacogenomics & Bioinformatics MedImmune
Talk Title: Identification of critical patient selection biomarkers for Luminal-B breast cancer subtypes
Talk Time: Stream 2 PM, 20th June
Tim Yeatman
Director Gibbs Cancer Center
Talk Title: The vital importance of increasing patient access to personalized therapies: A physician’s roadmap
Talk Time: Plenary session PM, 20th June
Tammie Yeh
Molecular Biomarkers, Oncology Lead Merck
Talk Title: Incorporating biomarker strategies early on in oncology programs
Talk Time: Stream 2 PM, 19th June Read more...
Cyrus Arman
Principal Deallus Consulting
Talk Title: CDx – and Evolving Value Proposition
Talk Time: Plenary session AM, 20th June Read more...